Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 23, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio CEO Appears on Executive Leaders Radio Program

BERWYN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
July 20, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania

BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
July 07, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients

BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
June 16, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study

BERWYN, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
June 09, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio to Present at the June 2020 Virtual Summer Investor Summit

BERWYN, Pa., June 09, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
June 02, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401

BERWYN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
June 01, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020

BERWYN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
May 27, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio Files Patent Application for Method of Inhibiting, Preventing, or Treating Neurological Injuries Due to Viral and Other Infections Including COVID-19

BERWYN, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
May 01, 2020 06:00 ET | Source: Annovis Bio Inc.

Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report

BERWYN, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...
April 30, 2020 06:45 ET | Source: Annovis Bio Inc.

Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients

BERWYN, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...